HCV Archives – Page 2 of 30 – Treatment Action Group

Health Activist Groups: Defunding UNRWA in Gaza Is an Act of Depravity and Enables a Genocide

January 30, 2024
Dorrit Walsh

We are appalled. As organisations that have historically worked on issues of health justice and access to medicines for millions of people around the world, for decades, focusing on HIV/AIDS, TB, cancer, and COVID, we share the urgent concern and outrage of aid organizations (NGOs) that the sudden decision by global north donor countries to suspend funding for the United Nations Relief and Works Agency (UNRWA) ‘’comes amid a rapidly worsening humanitarian catastrophe in Gaza."

NOW Is the Time for Hepatitis C Virus Elimination

January 10, 2024
Dorrit Walsh

Hepatitis C-related liver diseases continue to kill an estimated 15,000 people per year in the United States, despite the availability of an effective cure.

Communities as Actors in the Research and Development Process

December 13, 2023
Dorrit Walsh

This publication explores the role of community engagement in health-related research and development (R&D), particularly within the Unitaid-funded LONGEVITY Project.

Submission on the Right to Access and Take Part in Scientific Progress

November 16, 2023
Dorrit Walsh

TAG is a longstanding champion of the human right to science, which we believe entitles everyone, everywhere to benefit from the best available tools to end HIV, TB, and HCV.

Treatment Action Group Calls for Immediate Ceasefire in Gaza to Protect Health and Lives

November 6, 2023
Dorrit Walsh

Treatment Action Group (TAG) urgently calls for an immediate ceasefire in Gaza. We grieve Israeli and Palestinian lives lost before, on, and since October 7, and unequivocally condemn the Hamas attacks that killed more than 1,400 Israelis, including some 30 children.

October 2023 TAGline cover: Lost in Translation. Features graphic of "TAG Translate" and shows 4 sets of terms: Shorter Treatments = Error: Insufficient Funding; Community Engagement = Error: political hostility; effective prevention = error inadequate awareness; broad screening = error: outdated guidelines

TAGline October 2023

October 4, 2023
Dorrit Walsh

We’re thrilled to share the 2023 edition of TAGline, which explores some of the barriers that obstruct research from being effectively implemented to improve people’s health.

TAG to Honor Leaders of Latino HIV Community, Pediatric Drug-Resistant TB, and Transgender Health at RIAA 2023

September 12, 2023
Dorrit Walsh

Our annual Research in Action Awards (RIAA) event is TAG’s biggest night of the year. On October 19, we’ll be deeply honored to gather with our most cherished supporters and community members to recognize just a few of the many visionaries whose work has brought us closer to ending HIV, TB, and HCV.

HCV Elimination Among People Living with and at Risk of HIV: Challenges and Opportunities

September 5, 2023
Dorrit Walsh

Following the White House’s recent proposal for a National Hepatitis C Elimination Plan as part of its Fiscal Year 2024 budget request to Congress, and the fact that key populations for HIV are also at high risk of HCV, Treatment Action Group is organizing a webinar that will highlight best practices and challenges for HCV elimination with a specific focus on high-burden populations.

TAG Welcomes Addition of Ravidasvir to WHO Essential Medicines List for Treatment of Hepatitis C Virus

August 2, 2023
Dorrit Walsh

Treatment Action Group welcomes the inclusion of Ravidasvir on the World Health Organization (WHO) Essential Medicines List (EML) as a direct-acting antiviral (DAA) for the treatment of chronic hepatitis C virus (HCV) infection in adults.

2023 Pipeline Report

July 20, 2023
Dorrit Walsh

Pipeline Report provides an overview of research and provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB).